January 24, 2011
* Gilenya offers an alternative to frequent injections, which is a major advance for people with relapsing-remitting multiple sclerosis in Switzerland and Australia
* Gilenya showed enhanced efficacy to interferon beta-1a IM, a commonly
prescribed treatment, reducing relapses by 52% (p<0.001) at one year
* Two-year, placebo-controlled study demonstrated that Gilenya significantly reduced the risk of disability progression
Basel, January 24, 2011 – Swissmedic, the Swiss Agency for Therapeutic Products, and the Australian Therapeutic Goods Administration (TGA) have granted approval for Gilenya(®) (fingolimod) 0.5 mg as a first-line, oral disease-modifying therapy (DMT) for the treatment of relapsing-remitting multiple sclerosis
(RRMS).
“Gilenya, with its innovative mechanism of action, can improve clinical outcomes in patients with relapsing remitting MS, ” said Professor Ludwig Kappos, Neurology and Department of Research, University Hospital, Basel, Switzerland. “The significant efficacy and manageable safety profile of Gilenya make it a valuable new option for patients with relapsing-remitting MS and the physicians
who treat them.”
Continue Reading – Click here
* Gilenya offers an alternative to frequent injections, which is a major advance for people with relapsing-remitting multiple sclerosis in Switzerland and Australia
* Gilenya showed enhanced efficacy to interferon beta-1a IM, a commonly
prescribed treatment, reducing relapses by 52% (p<0.001) at one year
* Two-year, placebo-controlled study demonstrated that Gilenya significantly reduced the risk of disability progression
Basel, January 24, 2011 – Swissmedic, the Swiss Agency for Therapeutic Products, and the Australian Therapeutic Goods Administration (TGA) have granted approval for Gilenya(®) (fingolimod) 0.5 mg as a first-line, oral disease-modifying therapy (DMT) for the treatment of relapsing-remitting multiple sclerosis
(RRMS).
“Gilenya, with its innovative mechanism of action, can improve clinical outcomes in patients with relapsing remitting MS, ” said Professor Ludwig Kappos, Neurology and Department of Research, University Hospital, Basel, Switzerland. “The significant efficacy and manageable safety profile of Gilenya make it a valuable new option for patients with relapsing-remitting MS and the physicians
who treat them.”
Continue Reading – Click here
***************************************************************
If you find our information worthy,
then please donate by clicking here
****************************************************************
“Providing You with ‘MS Views and News’, is what we do“
.
REMAIN up–to–date with educational information of
Multiple Sclerosis when registered at
the MS Views and News website.
.
****************************************************************
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews